Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, PR China.
Bioanalysis. 2020 Jul;12(14):991-1001. doi: 10.4155/bio-2020-0098. Epub 2020 Jul 22.
To optimize clinical efficacy and reduce the drug-exposure-related toxicity of linezolid, whose concentrations show wide inter-variabilities, a simple and reliable quantitative assay for therapeutic drug monitoring is necessary. A UHPLC-MS/MS assay has been established for determination of linezolid in human plasma and fully validated according to the US FDA guidelines. After a simple, isotope-dilluted precipitation with methanol, the analytes were separated by a straightforward isocratic mode and the MS/MS was conducted under the ESI mode fitted with SRM. The calibration curves proved acceptable linearity in the range of 0.1-30.0 µg/ml. The present assay is currently used in routine clinical practice, being applied to therapeutic drug monitoring and helps to optimize individual dosing regimens and manage adverse effects in ICU patients.
为了优化利奈唑胺的临床疗效并降低其药物暴露相关毒性(其浓度存在广泛的个体差异),有必要建立一种简单可靠的治疗药物监测定量分析方法。本研究建立了一种 UHPLC-MS/MS 测定人血浆中利奈唑胺浓度的方法,并根据美国 FDA 指南进行了全面验证。采用甲醇同位素稀释沉淀法进行简单预处理后,采用直接等度洗脱模式进行分离,ESI 模式下采用选择反应监测(SRM)进行 MS/MS 检测。校准曲线在 0.1-30.0μg/ml 范围内具有可接受的线性。目前该方法已用于常规临床实践,用于治疗药物监测,有助于优化 ICU 患者的个体化给药方案和管理不良反应。